Canada Achieves New Psychedelic Milestone After Holding First Psilocybin Therapy Group Session
Canada held its first legal psilocybin therapy group session recently. Psilocybin is an active hallucinogenic compound found in magic mushrooms. Various studies conducted by major research institutions have found that psilocybin possesses therapeutic benefits. For instance, studies by Johns Hopkins University, New York University and the University of California Los Angeles have discovered that psilocybin can be used to effectively decrease end-of-life distress in patients with terminal conditions.
The session, which was hosted in Vancouver, British Columbia, was facilitated by My Community Journeys, a not-for-profit health-care organization. The therapy session included nine end-of-life patients who had received legal exemptions from the country’s Federal Minister of Health under the country’s Controlled Drugs and Substances Act.
The exemptions, which were granted on a case-by-case basis for patients suffering from end-of-life distress after being diagnosed with a terminal illness such as cancer, permitted the patients to access therapeutic psilocybin and allowed certified and trained professionals to administer this treatment to them.
Dr. Valoria Masuda, a palliative care physician and the session’s facilitator, stated that those in charge had worked with Health Canada to make sure that all parameters and measures were in place to provide a compassionate and safe experience for the session’s participants. While this particular session didn’t charge the patients, some therapists have been providing therapy sessions at $2,000 and above as the demand for psilocybin therapy increases in the country.
Masuda maintained that psilocybin therapy needed to be a part of publicly funded healthcare in order for all to access it, instead of only those who could afford to pay for the services.
All the participants met before they took part in their first session to allow them to familiarize themselves with each and other and be comfortable sharing their feelings and thoughts freely. After their first therapy session, some participants admitted to having a profound experience while others stated that it was incredibly healing and moving.
Given that many end-of-life patients suffer from mental health conditions such as depression and anxiety brought on by their diagnosis in addition to the physical pain associated with a terminal condition, the session was hailed as a success. Psychedelic-assisted therapy offers new hope and a new way for patients with terminal illnesses to obtain relief. Currently, the primary options for relief from their suffering for these patients include medical assistance in dying and terminal sedation, which entails the administration of drugs that help keep a patient sedated till they succumb to their illness.
This win for the psychedelic sector is a positive development for the industry and all sector actors, including Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF), since the mainstreaming of the industry has just taken a huge step forward.
NOTE TO INVESTORS: The latest news and updates relating to Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) are available in the company’s newsroom at https://ibn.fm/MYCOF
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Canada held its first legal psilocybin therapy group session recently. Psilocybin is an active hallucinogenic compound found in magic mushrooms. Various studies conducted by major research institutions have found that psilocybin possesses therapeutic benefits. For instance, studies by Johns Hopkins University, New York University and the University of California Los Angeles have discovered that psilocybin can be used to effectively decrease end-of-life distress in patients with terminal conditions.
The session, which was hosted in Vancouver, British Columbia, was facilitated by My Community Journeys, a not-for-profit health-care organization. The therapy session included nine end-of-life patients who had received legal exemptions from the country’s Federal Minister of Health under the country’s Controlled Drugs and Substances Act.
The exemptions, which were granted on a case-by-case basis for patients suffering from end-of-life distress after being diagnosed with a terminal illness such as cancer, permitted the patients to access therapeutic psilocybin and allowed certified and trained professionals to administer this treatment to them.
Dr. Valoria Masuda, a palliative care physician and the session’s facilitator, stated that those in charge had worked with Health Canada to make sure that all parameters and measures were in place to provide a compassionate and safe experience for the session’s participants. While this particular session didn’t charge the patients, some therapists have been providing therapy sessions at $2,000 and above as the demand for psilocybin therapy increases in the country.
Masuda maintained that psilocybin therapy needed to be a part of publicly funded healthcare in order for all to access it, instead of only those who could afford to pay for the services.
All the participants met before they took part in their first session to allow them to familiarize themselves with each and other and be comfortable sharing their feelings and thoughts freely. After their first therapy session, some participants admitted to having a profound experience while others stated that it was incredibly healing and moving.
Given that many end-of-life patients suffer from mental health conditions such as depression and anxiety brought on by their diagnosis in addition to the physical pain associated with a terminal condition, the session was hailed as a success. Psychedelic-assisted therapy offers new hope and a new way for patients with terminal illnesses to obtain relief. Currently, the primary options for relief from their suffering for these patients include medical assistance in dying and terminal sedation, which entails the administration of drugs that help keep a patient sedated till they succumb to their illness.
This win for the psychedelic sector is a positive development for the industry and all sector actors, including Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF), since the mainstreaming of the industry has just taken a huge step forward.
NOTE TO INVESTORS: The latest news and updates relating to Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) are available in the company’s newsroom at https://ibn.fm/MYCOF
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
